

Forward Pharma (*Nasdaq:FWP*) Corporate Update

October 2, 2018




Claus Bo Svendsen, MD, PhD
Chief Executive Officer

Forward-Looking Statements

Certain statements in this presentation may constitute “forward-looking statements” of Forward Pharma A/S within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements which contain language such as “believe”, “expect”, “anticipate”, “estimate”, “would”, “may”, “plan” and “potential”. Forward-looking statements are predictions only, which involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from those expressed in such statements. Many such risks, uncertainties and other factors are taken into account as part of our assumptions underlying these forward-looking statements and include, among others, risks related to the following: the satisfaction of certain conditions, and the accuracy of certain representations of the Company, in the Settlement and License Agreement entered into with subsidiaries of Biogen Inc. and certain other parties thereto; our ability to obtain, maintain, enforce and defend issued patents with royalty-bearing claims; our ability to prevail in the interference proceeding after all appeals and obtain issuance of the '871 application; our ability to prevail in or obtain a favorable decision in the '355 European Opposition Proceedings, after all appeals; the expected timing for key activities and an ultimate ruling in such legal proceedings; the issuance and term of our patents; future sales of Tecfidera[®], including impact on such sales from competition, generic challenges, regulatory involvement and pricing pressures; the scope, validity and enforceability of our intellectual property rights in general and the impact on us of patents and other intellectual property rights of third parties; and our ability to generate revenue from product sales in the U.S. directly or through an assignee of our U.S. co-exclusive license rights in the event Biogen does not obtain an exclusive license from us in the U.S. Certain of these and other risk factors are identified and described in detail in certain of our filings with the United States Securities and Exchange Commission, including our Annual Report on Form 20-F for the year ended December 31, 2017. We are providing this information as of the date of this presentation and do not undertake any obligation to update any forward-looking statements contained in this presentation as a result of new information, future events or otherwise.


- Tecfidera[®] (DMF) remains a leading therapy for multiple sclerosis
 - Global sales: 2017 (\$ 4.2 B); 2022 (forecast to \$4.46 B)
 - US sales ~80%; ex-US sales ~20%
- FWP has IP-gated access to future royalties on Tecfidera[®] sales
 - Irrevocable license to all DMF IP granted to Biogen in January 2017
 - Potential future royalties on Tecfidera[®] sales dependent on
 - *in US*: upcoming legal decision expected in 2018
 - *outside US*: outcome of appeal of Opposition Division decision
- Business optimized to support ongoing IP strategy and continuing obligations per Settlement and License Agreement
- Capital reduction and shareholder distribution of EUR 917.7 M effected September 2017

Share Value Drivers under the Settlement and License Agreement




1. Analyst consensus estimates, EvaluatePharma, May 2017. Not meant to be comprehensive; size of boxes is arbitrary and not meant to illustrate comparative differences in amounts. Appropriate risk-adjustment should be applied. Potential investors and current shareholders are strongly urged to read the Settlement and License Agreement in its entirety as well as our Annual Report on Form 20-F for the year ended December 31, 2017, where risk factors are identified and described in detail.

Risk-Reward guides choice of therapy in MS





Adapted from Coles A, Newer therapies for multiple sclerosis. Ann Indian Acad Neurol 2015;18, Suppl S1:30-4

Factors Influencing Future Tecfidera® Sales




- **Regulatory Data Exclusivity and Patent Protection**
 - Settlement and License Agreement adds Forward Pharma IP
- **Overall drug pricing trends**
- **Potential generic entrants and additional S1P modulators**

Gating Events for Royalties on Tecfidera® Net Sales




The summary of the Settlement and License Agreement in this presentation does not purport to be complete and is subject to, and qualified in its entirety by, the full text of the Settlement and License Agreement, which is available on Forward's website. Potential investors and current shareholders are strongly urged to read the Settlement and License Agreement in its entirety as well as our Annual Report on Form 20-F for the year ended December 31, 2017.

Rates on Potential Royalty of Tecfidera® Net Sales



(a) Subject to, among other things, expiration or invalidation of the patents or impact of generic entry on a country-by-country basis, as defined in the Settlement and License Agreement
 (b) Royalties payable on a country-by-country basis on DMF-containing products indicated for MS that, but for the Settlement and License Agreement, would infringe a Forward licensed patent

Timeline for IP litigation in U.S.



Dates represent current estimates of the timeline; a green tick mark signifies actual date of completed event.

Documents for the US appeal can be located through <https://ecf.cafc.uscourts.gov/>

- **Interference declared April 13, 2015**

A patent interference is an administrative proceeding at the Patent and Trial Appeal Board (PTAB) of the U.S. Patent and Trademark Office (USPTO) used to determine which party is the first to invent a common invention claimed by both parties.

- **Forward awarded “Senior Party” status**

The Senior Party has the earliest effective filing date to the common invention; entitled to the presumption that it is the first inventor.

- **On March 31, 2017, the USPTO PTAB ruled in favor of Biogen**


Without addressing which party was the first to invent the common invention claimed by both parties, the PTAB concluded that the Forward patent application did not have sufficient written description support for the claimed invention.

- **Forward is appealing the ruling to the U.S. Court of Appeals for the Federal Circuit**

Specialist team led by Kathleen Sullivan from Quinn Emanuel Urquhart & Sullivan, LLP. Oral argument held on June 4, 2018. Decision awaited.

Should the Forward appeal be successful, the interference will be returned to the USPTO to resume the interference proceedings. After completion of the interference proceedings, a further appeal to the U.S. Court of Appeals is possible.

Timeline for the appeal of the first instance decision in the EP'355 Opposition Proceedings



Dates represent current estimates of the timeline; a green tick mark signifies actual date of completed event.
Documents can be located through <https://register.epo.org/regviewer>

- EP2801355 patent granted by European Patent Office (EPO) on May 20, 2015
- Subject to several oppositions filed with the EPO by third parties (including Biogen)
- On January 29, 2018, the Opposition Division of the EPO revoked the EP'355 patent
- Appeal of the decision of the Opposition Division to the Technical Board of Appeal initiated on May 7, 2018, with expected conclusion in an additional 2-3 years.

Balance Sheet and Operating Results

Current per June 30, 2018



- Capital Reduction completed in September 2017
 - EUR 917.7 M distributed to shareholders
 - Staff reduced to 5 employees (Management and Finance function)


- **Share information** (per September 27, 2018)
 - Closing price per ADS: \$ 2.22
 - Market Cap: \$ 105.5 M
 - Number of issued shares: 95,073,864, of which ~24% are listed as American Depositary Shares (ADS)
(*Ticker: FWP; 1 ADS represents 2 shares*)

<u>Balance Sheet</u>	At June 30, 2018 USD '000s
Cash	\$ 89,261
Other assets	1,204
Total assets	90,465
Total shareholder equity	85,215
Total liabilities	5,250
Total shareholder equity and liabilities	<u>\$ 90,465</u>

<u>Operating Results</u>	Six months ended June 30, 2018 USD '000s
Revenue	\$ -
Operating expenses*	(7,646)
Other income	2,172
Income tax benefit	204
Net loss	<u>\$ (5,270)</u>

* Includes non-cash share-based compensation of \$ 3.7 million

Share Value Drivers under the Settlement and License Agreement



1. Analyst consensus estimates, EvaluatePharma, May 2017. Not meant to be comprehensive; size of boxes is arbitrary and not meant to illustrate comparative differences in amounts. Appropriate risk-adjustment should be applied. Potential investors and current shareholders are strongly urged to read the Settlement and License Agreement in its entirety as well as our Annual Report on Form 20-F for the year ended December 31, 2017, where risk factors are identified and described in detail.

- **Qualifiers for future royalty from Tecfidera® sales**
 - **Appeal of the U.S. PTAB interference decision to the Federal Circuit**
 - Oral Argument – June 4, 2018
 - **Expected Decision – H2/2018**

 - **European EP'355 Opposition Proceedings**
 - Appeal initiated – May 7, 2018
 - **Filing of statement of grounds of appeal – August 1, 2018**

Claus Bo Svendsen, MD, PhD
Chief Executive Officer

Forward Pharma Investor Relations
investors@forward-pharma.com

US Potential Royalty-Bearing Claims

4 patent applications are currently pending that, if issued, may contain claims that may be royalty-bearing if Forward obtains a Relevant Patent after all appeals in the Interference Proceeding

	Application Number	Description
US	11/576,871	Treating MS with DMF at 480 mg/day Interference declared; FWP as Senior Party – April 13, 2015 PTAB ruled in favor of Biogen – March 31, 2017 Appeal to the Federal Circuit awaiting decision; oral argument – June 4, 2018
	16/046,509	Filed July 26, 2018 Application pending (not yet published), not yet examined
	14/212,503	Treating MS with DMF at 480 mg/day to reach certain MMF levels in the bloodstream On appeal from final rejection
	15/988,628	Filed May 24, 2018 Application pending (not yet published), not yet examined

A Relevant Patent is a patent that covers treatment for MS by orally administering 480 mg per day of DMF.

If we prevail in the Interference Proceeding after any appeals to the Federal Circuit, we further expect the 11/576,871 application, if ultimately issued, would be entitled to patent term adjustment that would result in an estimated patent expiration in 2029 or later. There is no assurance that patent term adjustment would be obtained to fully compensate for all such time lost.

Ex-US Potential Royalty-Bearing Claims

If Forward obtains a Relevant Patent in the European EP'355 opposition proceedings including all appeals therefrom, and can show on a country-by-country basis that Tecfidera® infringes a valid licensed patent, royalties may be payable. In Europe, there are presently four patents and patent applications with potentially royalty-bearing claims.

	Application Number	Description
Ex-US	EP14172398.1 (Pat. No. EP2801355)	Treating MS with 480 mg/day of DMF wherein the pH controlled release compositions have an enteric coat Revoked by Opposition Division – January 29, 2018 Appeal filed – May 7, 2018
	EP15166243.4 (Pat. No. EP2965751)	Treating MS with 480-600 mg fumaric acid esters (including DMF)/day where the composition releases fumaric acid esters depending on pH. Application pending
	EP14172396.5 (Pat. No. EP2792349)	Controlled release composition of DMF for use in treating hyperproliferative, inflammatory or autoimmune disorders other than psoriasis with 480 mg/day Application pending
	EP16001391.8 (Pat. No. EP3093012)	Controlled release pharmaceutical composition comprising DMF in an amount of 50-90% by weight Application pending

A Relevant Patent is a patent that covers treatment for MS by orally administering 480 mg per day of DMF.

Key IP Overview:

Core Composition and Erosion Matrix Patent Families¹

Patent / Application	Patent Family	Status
U.S. App. 11/576,871	Core Composition	Pending and involved in an interference proceeding. A decision was issued by the PTAB on March 31, 2017 in favor of Biogen. Currently under appeal with the Federal Circuit.
U.S. App. 16/046,509	Core Composition	Pending.
U.S. App. 14/212,503	Core Composition	On appeal from final rejection.
U.S. App. 15/988,628	Core Composition	Pending.
EP2801355	Core Composition	Revoked by decision of January 29, 2018; under appeal.
EP1799196	Core Composition	Granted. Under opposition with EPO.
EP2801354	Core Composition	Granted. Under opposition with EPO.
EP3093012	Core Composition	Pending.
EP2965751	Core Composition	Pending.
EP2792349	Core Composition	Pending.
U.S. Patent No. 8,906,420	Erosion Matrix	Granted.
U.S. App. 15/945,005	Erosion Matrix	Pending.
EP2379063	Erosion Matrix	Granted; opposition rejected; appeal pending.
EP2564839	Erosion Matrix	Granted. Under opposition with EPO.
EP3295936	Erosion Matrix	Pending.
JP5788331	Erosion Matrix	Granted as JP2012-514624.

1. Beyond the core composition patent and erosion matrix patent families, other patent families include U.S. Patent Application Nos. 16/046,028, 15/979,894 and European Patent Application Nos. EP2879672, EP3038606 and EP3038605. As a result of the corporate restructuring that was completed pursuant to Appendix D of the Settlement and License Agreement, the intellectual property of Forward Pharma that is the subject of the Settlement and License Agreement was ultimately transferred to FWP IP ApS, a Danish limited liability company, and the capital stock of FWP IP ApS was transferred to a newly formed independent Danish foundation. For more information regarding this restructuring and transfer, see our Form 6-K and press release dated November 22, 2017.

Date of preparation: August 17, 2018